ACTINIUM PHARMACEUTICALS, INC. Restricted Cash and Cash Equivalents
ACTINIUM PHARMACEUTICALS, INC. (ATNM) had Restricted Cash and Cash Equivalents of $40.10 thousand as of 2019-03-31, per its 10-Q filed 2019-05-10.
Discontinued › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2019-05-10
- 2019-03-31: Restricted Cash and Cash Equivalents $40.10K.
- 2018-12-31: Restricted Cash and Cash Equivalents $40.08K.
- 2018-09-30: Restricted Cash and Cash Equivalents $40.05K.
- 2018-06-30: Restricted Cash and Cash Equivalents $40.03K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2019-03-31 | $40.10K 10-Q · filed 2019-05-10 |
| 2018-12-31 | $40.08K 10-Q · filed 2019-05-10 |
| 2018-09-30 | $40.05K 10-Q · filed 2018-11-09 |
| 2018-06-30 | $40.03K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $40.01K 10-Q · filed 2018-05-10 |
| 2016-12-31 | $34.73K 10-K · filed 2018-03-16 |
| 2016-09-30 | $34.73K 10-Q · filed 2016-10-28 |
| 2016-06-30 | $34.73K 10-Q · filed 2016-07-29 |
| 2016-03-31 | $34.73K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $34.73K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |